Lithium aspartate fails to improve long COVID symptoms, but higher doses may hold promise
Lithium aspartate at 10-15 mg/d is ineffective for treating cognitive dysfunction and fatigue in long COVID, but higher doses may offer potential benefits based...
Initial trials of low-dose lithium failed to improve long COVID symptoms, but new findings suggest higher doses could offer hope for patients suffering from fat...
Read More
Other Stories in Health
- Dietary zinc may reduce plasmid transfer in gut microbes
- Lithium aspartate fails to improve long COVID symptoms, but higher doses may hold promise
- Two California farm works test positive for bird flu
- University of Rochester MSN 2019
- Scientists identify gut microbial signatures that distinguish diseases and predict health states
- Depression and anxiety diagnoses in youth spiked during the COVID-19 pandemic
- CARBIOS announces half-year 2024 financial results and presents its industrial and commercial progress
- CARBIOS annonce ses Résultats semestriels 2024 et présente ses avancées industrielles et commerciales
- CARBIOS berichtet Finanzergebnisse für das erste Halbjahr 2024 und Fortschritte in Richtung Industrialisierung und Kommerzialisierung
.png)
